



29 August 2023

Medicine Supply Alert Notice

Jext[®] 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injector pen

Priority: Level 2*

Valid until: w/c 11th September 2023

Issue

1. Jext[®] 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injector pens are out of stock until w/c 11th September 2023.
2. EpiPen[®] 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injector pens remain available and can support a full uplift in demand.
3. Jext[®] 150 micrograms/0.15mL (1 in 1000) solution for injection auto-injector pens remain available.
4. A Serious Shortage Protocol (SSP) was issued on 25/08/2023. The details of this SSP can be accessed at: [Serious shortage protocol: Jext[®] 300 micrograms/0.3ml \(1 in 100\) solution for injection auto-injector pen \(scot.nhs.uk\)](https://www.scot.nhs.uk/serious-shortage-protocols/serious-shortage-protocol-jext-300-micrograms-0.3ml-1-in-100-solution-for-injection-auto-injector-pen)

Advice and Actions

5. All healthcare professionals in primary, secondary and tertiary care who prescribe or dispense Jext[®] 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injector pens should:
 - not initiate new patients onto Jext[®] 300 micrograms/0.3mL (1 in 1000) solution for injection autoinjector pens during the period of the shortage.
6. Pharmacists may supply EpiPen[®] 300 micrograms/0.3mL auto-injector pens in accordance with the SSP for eligible patients (see Additional Information):
 - pharmacists must ensure that the patient's prescriber and/or GP practice is notified when supplying a patient in accordance with this SSP; and
 - patients should be counselled regarding the switch in device at the point of supply and given device-specific training (how to use) as well as when to use.
7. If the patient is deemed ineligible or does not consent to receive an alternative product via the SSP, clinicians in primary and secondary care can consider prescribing:
 - EpiPen[®] 300 micrograms/0.3mL auto-injector pens, and counsel patients regarding the change in device at the point of prescribing, including how to use the new device if patients are unfamiliar with EpiPen, and signposting to training materials (see Additional Information).

Additional Information

8. Please see the following links for further information:

- [SmPC Jext](#)
- [Jext 300microgram/0.3ml auto-injector pens SSP](#)
- [SmPC EpiPen](#)
- [Patient information leaflet on EpiPen](#)
- [EpiPen training video](#)
- [EpiPen trainer](#)
- [EpiPen explained](#)
- [BSACI guidance on adrenaline autoinjector](#)
- [Adrenaline auto-injectors: updated advice after European review](#)
- [MHRA - Adrenaline auto-injectors](#)
- [Adrenaline auto-injectors \(AAs\): new guidance and resources for safe use](#)
- [BNF adrenaline autoinjectors](#)

Specialist Pharmacy Service (SPS) website

9. The UK Department of Health and Social Care (DHSC) in conjunction with SPS have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues.
10. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
11. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool in order to stay up to date concerning medicines supply disruptions.
12. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

13. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).